245 related articles for article (PubMed ID: 21084819)
21. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.
Cameron D; Casey M; Press M; Lindquist D; Pienkowski T; Romieu CG; Chan S; Jagiello-Gruszfeld A; Kaufman B; Crown J; Chan A; Campone M; Viens P; Davidson N; Gorbounova V; Raats JI; Skarlos D; Newstat B; Roychowdhury D; Paoletti P; Oliva C; Rubin S; Stein S; Geyer CE
Breast Cancer Res Treat; 2008 Dec; 112(3):533-43. PubMed ID: 18188694
[TBL] [Abstract][Full Text] [Related]
22. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
Arslan UY; Turker I; Aksoy S; Oksuzoglu B; Helvaci K; Yildirim Ozdemir N; Uyeturk U; Uysal Sonmez O; Budakoglu B; Zengin N
J BUON; 2013; 18(3):585-93. PubMed ID: 24065468
[TBL] [Abstract][Full Text] [Related]
23. [Two cases of recurrent breast cancer with regional lymph node metastases showing a complete response to trastuzumab and paclitaxel treatment].
Ohsako T; Inoue K; Nagamoto N; Yoshida Y; Nakahara O
Gan To Kagaku Ryoho; 2006 Sep; 33(9):1301-3. PubMed ID: 16969029
[TBL] [Abstract][Full Text] [Related]
24. Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine.
Metro G; Foglietta J; Russillo M; Stocchi L; Vidiri A; Giannarelli D; Crinò L; Papaldo P; Mottolese M; Cognetti F; Fabi A; Gori S
Ann Oncol; 2011 Mar; 22(3):625-630. PubMed ID: 20724575
[TBL] [Abstract][Full Text] [Related]
25. Early-onset brain metastases in a breast cancer patient after pathological complete response to neoadjuvant chemotherapy.
Shimada K; Ishikawa T; Yoneyama S; Kita K; Narui K; Sugae S; Shimizu D; Tanabe M; Sasaki T; Chishima T; Ichikawa Y; Endo I
Anticancer Res; 2013 Nov; 33(11):5119-21. PubMed ID: 24222158
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer.
Babacan T; Efe O; Hasirci AS; Demirci F; Buyukhatipoglu H; Balakan O; Sarici F; Kertmen N; Esin E; Akin S; Ates O; Aksoy S; Sever AR; Altundag K
Tumori; 2015; 101(4):418-23. PubMed ID: 25953439
[TBL] [Abstract][Full Text] [Related]
27. Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian Society of Medical Oncology.
Kaplan MA; Isikdogan A; Koca D; Kucukoner M; Gumusay O; Yildiz R; Dayan A; Demir L; Geredeli C; Kocer M; Arslan UY; Inal A; Akman T; Coskun U; Sener N; Inanc M; Elkiran ET; Ozdemir NY; Durnalı AG; Suner A; Alici S; Tarhan MO; Boruban C; Oksuzoglu B; Urakci Z
Breast Cancer; 2014 Nov; 21(6):677-83. PubMed ID: 23335064
[TBL] [Abstract][Full Text] [Related]
28. [A case of trastuzumab-resistant breast cancer responding to lapatinib/capecitabine therapy].
Hayashi M; Orita M; Hironaka H; Morita N
Gan To Kagaku Ryoho; 2014 Mar; 41(3):353-5. PubMed ID: 24743282
[TBL] [Abstract][Full Text] [Related]
29. [The case of a long-surviving patient with breast cancer and brain metastases treated using multidisciplinary therapy].
Nishimura A; Nishi T; Morohashi S; Okano K; Hakamada K
Gan To Kagaku Ryoho; 2014 Nov; 41(12):1897-9. PubMed ID: 25731368
[TBL] [Abstract][Full Text] [Related]
30. [A case of HER2-positive breast cancer receiving lapatinib+capecitabine chemotherapy with ventriculoperitoneal shunting for hydrocephalus associated with brain metastases].
Makino T; Kawamura H; Yokoyama E; Kato Y; Nishina M
Gan To Kagaku Ryoho; 2012 Jul; 39(7):1115-7. PubMed ID: 22790050
[TBL] [Abstract][Full Text] [Related]
31. Lapatinib for the treatment of HER2-overexpressing breast cancer.
Jones J; Takeda A; Picot J; von Keyserlingk C; Clegg A
Health Technol Assess; 2009 Oct; 13 Suppl 3():1-6. PubMed ID: 19846022
[TBL] [Abstract][Full Text] [Related]
32. Bilateral inflammatory metachronic ERBB2 (HER2/neu)-positive breast carcinoma: prolonged survival with combined chemotherapy and trastuzumab.
Lázaro A; Casinello J; Amorós A; Heredia M; López-Alfonso A
Clin Transl Oncol; 2008 Sep; 10(9):587-90. PubMed ID: 18796377
[TBL] [Abstract][Full Text] [Related]
33. Over 17-month complete clinical brain response with a well-tolerated lapatinib plus capecitabine combination in a very young patient afflicted by HER2-positive metastatic breast cancer.
Sini V; Menghi A; Cursano MC; Mandolini PL; Lanza R
Tumori; 2013; 99(6):273e-7e. PubMed ID: 24503802
[TBL] [Abstract][Full Text] [Related]
34. [A case of effective lapatinib/capecitabine therapy for HER2-positive breast cancer with multiple brain metastases].
Fujita Y; Mizuta N; Sakaguchi K; Nakatsukasa K; Imai A; Umeda Y; Hamaoka A; Morita M; Shouji M; Goto M; Taguchi T
Gan To Kagaku Ryoho; 2012 Nov; 39(11):1699-702. PubMed ID: 23152022
[TBL] [Abstract][Full Text] [Related]
35. On and off metronomic oral vinorelbine in elderly women with advanced breast cancer.
De Iuliis F; Salerno G; Taglieri L; Lanza R; Scarpa S
Tumori; 2015; 101(1):30-5. PubMed ID: 25702645
[TBL] [Abstract][Full Text] [Related]
36. Severe drug-induced thrombocytopenia after treatment with trastuzumab but not with lapatinib.
Cathomas R; von Moos R
Ann Oncol; 2009 Sep; 20(9):1606-1607. PubMed ID: 19622591
[No Abstract] [Full Text] [Related]
37. A case of metastatic breast cancer successfully treated with lapatinib plus capecitabine therapy.
Kefeli U; Bilici A; Ustaalioglu BB; Kefeli AU; Yildirim ME; Seker M; Gumus M
Arch Gynecol Obstet; 2011 Feb; 283(2):405-7. PubMed ID: 20495812
[No Abstract] [Full Text] [Related]
38. TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab.
Glück S; Ross JS; Royce M; McKenna EF; Perou CM; Avisar E; Wu L
Breast Cancer Res Treat; 2012 Apr; 132(3):781-91. PubMed ID: 21373875
[TBL] [Abstract][Full Text] [Related]
39. [A complete response of scirrhous gastric carcinoma treated with trastuzumab combination therapy].
Nishi T; Hamamoto Y; Uemoto J; Onodera K; Warita E; Yamanaka Y
Gan To Kagaku Ryoho; 2012 Dec; 39(13):2553-5. PubMed ID: 23235178
[TBL] [Abstract][Full Text] [Related]
40. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial.
von Minckwitz G; Kümmel S; Vogel P; Hanusch C; Eidtmann H; Hilfrich J; Gerber B; Huober J; Costa SD; Jackisch C; Loibl S; Mehta K; Kaufmann M;
J Natl Cancer Inst; 2008 Apr; 100(8):542-51. PubMed ID: 18398097
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
